Qihan Raises $67 Million for Gene Editing of Cell Therapies, Organ Transplant Drugs

Qihan Biotechnology, a Hangzhou gene editing company, raised $67 million in a Series A++ round to advance its portfolio of novel autologous cell therapies. The company uses its multiplexable genome editing technology to develop cell therapies and facilitate organ transplants. With the new capital, Qihan plans to conduct IND-enabling studies and hypoimmunity projects, plus expand its manufacturing facility. The round was backed by Lilly Asia Ventures, Matrix Partners China, Sequoia and CMB International. More details.... Share this with colleagues: // //